Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

ASNC1721 : A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Radiotherapy<br/>TrialTypeRadiotherapy
Trial

TwoPhase Two

3-25Age 3-25

Brain and Spinal<br/>CancersCancer LocationBrain and Spinal
Cancers

Radiotherapy,Systemic therapy | Brain and spinal cordAstrocytoma,Glioblastoma (GBM) ,Glioma

Trial Overview Read MoreRead more

This Phase II trial is evaluating the effectiveness of a combination of radiotherapy, chemotherapy (temozolomide) and another cancer drug (veliparib) is in treating people with newly diagnosed brain cancer without H3 K27M or BRAFV600 mutations.
 

This trial is treating patients with brain cancer.

This is a systemic therapy and radiotherapy trial.

You may be able to join this trial if:

  • You are able to swallow medication by mouth.
  • You have been diagnosed with cancer, but have not received any treatment.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations

Other Non-Commercial Sponsor

National Cancer Institute (NCI)

Summary

This trial has a single cohort that will go through two phases. Participants will first be treated with chemoradiotherapy. In this phase, they will receive veliparib (orally, twice daily) and will undergo 30 daily fractions of radiation therapy 5 days per week for 6-7 weeks in the absence of disease progression or unacceptable toxicity. Participants will then be treated with maintenance chemotherapy. This phase will begin 4 weeks after the chemoradiotherapy phase, and participants will receive veliparib (orally, twice daily) and temozolomide (orally, once daily) on days 1-5. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity.

Recruiting Hospitals Read MoreRead more

Monash Children's Cancer Centre
Clayton
Ms Irina Arzhintar
Irina.Arzhintar@monashhealth.org
(03) 8572 3490

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next